News

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...
Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...
The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.
Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants.
The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...
Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...
Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...
Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon in the fight against the mosquito-borne disease that is deadliest for ...
Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...